期刊
JOURNAL OF INFECTIOUS DISEASES
卷 223, 期 1, 页码 47-55出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa673
关键词
COVID-19; SARS-CoV-2; convalescent plasma; neutralizing antibodies
资金
- New York State Department of Health
Passive transfer of antibodies from COVID-19 convalescent patients is used as an experimental treatment for SARS-CoV-2 infections. As time post symptom onset increases, neutralizing activity in sera significantly rises to reach a peak, emphasizing the value of serum characterization for neutralization activity.
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration's (FDA) guidelines for convalescent plasma initially recommended target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at moderate (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity significantly increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was approximately 93% (PRNT50) and approximately 54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 enzyme-linked immunosorbent assay titers) showed maximal activity, but not all high-titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据